BioNTech | Investor Day Presentation Deck

Slide schematic 4/4

callout 1/1 chart 1/1 image 1/1 title 1/1

Components 4

primary line illustration headline

Tools 1

callout/primary: saRNA showed potential as a vaccine modality with much lower doses. Comparable immunogenicity with approximately 100-fold lower doses of saRNA compared to mRNA

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

before-after-framing 90%

Compares mRNA vs saRNA performance metrics

Find anything

The slide uses a combination of microscopy images and a line chart to demonstrate efficacy.